HYPEREOSINOPHILIC SYNDROME IN CHILDHOOD: Clinical and Molecular Features of Two Cases

REFERENCES

• Chusid M J, Dale D C, West B C, Wolff S M. The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1–27
   PubMed Web of Science ®Google Scholar
• Klion A D, Bochner B S, Gleich G J, , The Hypereosinophilic Syndromes Working G, et al. Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. J Allergy Clin Immunol. 2006; 117: 1292–1302
   PubMed Web of Science ®Google Scholar
• Golub T R, Barker G F, Lovett M, Gilliland D G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307–316
   PubMed Web of Science ®Google Scholar
• Bain B J. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004; 77: 82–85
   PubMed Web of Science ®Google Scholar
• Menssen H D, Renkl H J, Rieder H, et al. Distinction of eosinophilic leukaemia from idiopathic hypereosinophilic syndrome by analysis of Wilms’ tumour gene expression. Br J Haematol. 1998 May; 101: 325–334
   PubMed Web of Science ®Google Scholar
• Cilloni D, Messa F, Martinelli G, et al. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. Leukemia. 2007; 21: 1442–1450
   PubMed Web of Science ®Google Scholar
• Klion A D, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003; 101: 4660–4666
   PubMed Web of Science ®Google Scholar
• Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M. Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994; 1330: 535–538
   Google Scholar
• Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med. 2003; 54: 169–184
   PubMed Web of Science ®Google Scholar
• Alfaham M A, Ferguson S D, Sihra B, Davies J. The idiopathic hypereosinophilic syndrome. Arch Dis Child 1987; 62: 601–613
   PubMed Web of Science ®Google Scholar
• Spiegel R, Zalman L, Gavriel H, Horovitz Y. Hypereosinophilic syndrome in a child presenting as eosinophilic pharyngitis. J Pediatr Hematol Oncol. 2003; 25: 747–749
   PubMed Web of Science ®Google Scholar
• Pena Segura J L, Adrados I, Jimenez Bustos J M, Cabello A, Lopez Pison J. Eosinophilic myositis in a 9 year old boy. Rev Neurol. 2001; 33: 960–963
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Erdreich-Epstein A, deClerck Y, Coates T. Prolonged clinical response to vincristine treatment in two patients with idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol. 1992; 14: 348–351
   PubMedGoogle Scholar
• Rizzari C, Conter V, D’Angelo P, Cantu-Rajnoldi A, Masera G. Efficacy of prolonged low-dose steroid treatment in a child with idiopathic hypereosinophilic syndrome: A case report. Pediatr Hematol Oncol. 1995; 12: 209–212
   PubMed Web of Science ®Google Scholar
• Rives S, Alcorta I, Toll T, Tuset E, Estella J, Cross N C. Idiopathic hypereosinophilic syndrome in children: Report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement. J Pediatr Hematol Oncol. 2005; 27: 663–665
   PubMed Web of Science ®Google Scholar
• Fauci A S, Harley J B, Roberts W C, Ferrans V J, Gralnick H R, Bjornsen B H. NIH conference. The idiopathic hypereosinophilic syndrome: Clinical, pathophysiologic and therapeutic considerations. Ann Intern Med. 1982; 97: 78–92
   PubMed Web of Science ®Google Scholar
• Butterfield J H. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol Allergy Clin North Am. 2007; 27: 493–518
   PubMed Web of Science ®Google Scholar
• Marshall G M, White L. Effective therapy for a severe case of the idiopathic hypereosinophilic syndrome. Am J Pediatr Haematol Oncol. 1989; 11: 178–183
   PubMedGoogle Scholar
• Lee J H, Lee J W, Jang C S, et al. Successful cyclophosphamide therapy in recurrent eosinophilic colitis associated with hypereosinophilic syndrome. Yonsei Med J. 2002; 43: 267–270
   PubMed Web of Science ®Google Scholar
• Butterfield J H. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol. 2005; 114: 26–40
   PubMed Web of Science ®Google Scholar
• Yoon T Y, Ahn G B, Chang S H. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: Report of a case and literature review. J Dermatol. 2000; 27: 110–115
   PubMedGoogle Scholar
• Nadarajah S, Krafchik B, Roifman C, Horgan-Bell C. Treatment of hypereosinophilic syndrome in a child using cyclosporine: Implication for a primary T-cell abnormality. Pediatrics 1997; 99: 630–633
   PubMed Web of Science ®Google Scholar
• Chockalingam A, Jalil A, Shadduck R K, Lister J. Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Bone Marrow Transplant 1999; 23: 1093–1094
   PubMed Web of Science ®Google Scholar
• Schaller J L, Burkland G A. Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med. 2001; 3: 9
   PubMedGoogle Scholar
• Pottier P, Planchon B, Grossi O. Complete remission with imatinib mesylate (Glivec) of an idiopathic hyper-eosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha. Rev Med Interne. 2003; 24: 542–546
   PubMed Web of Science ®Google Scholar
• Salem Z, Zalloua P A, Chehal A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J. 2003; 4: 410–412
   PubMedGoogle Scholar
• Tan D, Hwang W, Ng H J, Goh Y T, Tan P. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: A case report. Int J Hematol. 2004; 80: 75–7
   PubMed Web of Science ®Google Scholar
• Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Hematol. 2008; 141: 200–204
   PubMed Web of Science ®Google Scholar
• Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory idiopathic hyper-eosinophilic syndrome with abnormal T cells: A case report. Br J Haematol 2004; 127: 477
   PubMedGoogle Scholar
• Rothenberg M E, Klion A D, Roufosse F E, et al. Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with Mepolizumab. N Engl J Med 2008; 358: 1215–1228
   PubMed Web of Science ®Google Scholar